Raj Wadwa
Concepts (320)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 121 | 2024 | 3258 | 8.910 |
Why?
| Insulin Infusion Systems | 39 | 2023 | 296 | 4.540 |
Why?
| Blood Glucose | 63 | 2024 | 1826 | 3.880 |
Why?
| Insulin | 44 | 2023 | 2083 | 3.290 |
Why?
| Hypoglycemic Agents | 43 | 2023 | 1008 | 3.190 |
Why?
| Blood Glucose Self-Monitoring | 38 | 2024 | 500 | 2.920 |
Why?
| Hypoglycemia | 25 | 2023 | 387 | 2.350 |
Why?
| Pancreas, Artificial | 16 | 2021 | 68 | 2.040 |
Why?
| Diabetic Angiopathies | 16 | 2019 | 244 | 1.730 |
Why?
| Vascular Stiffness | 14 | 2019 | 411 | 1.650 |
Why?
| Cardiovascular Diseases | 25 | 2019 | 1724 | 1.640 |
Why?
| Adolescent | 95 | 2024 | 17935 | 1.420 |
Why?
| Child | 73 | 2024 | 18537 | 1.160 |
Why?
| Telemedicine | 3 | 2022 | 667 | 1.000 |
Why?
| Diabetes Mellitus, Type 2 | 11 | 2020 | 2090 | 0.970 |
Why?
| Albuminuria | 4 | 2019 | 164 | 0.970 |
Why?
| Young Adult | 52 | 2023 | 10508 | 0.910 |
Why?
| Hyperglycemia | 11 | 2022 | 295 | 0.890 |
Why?
| Humans | 135 | 2024 | 115859 | 0.810 |
Why?
| Dyslipidemias | 4 | 2019 | 155 | 0.790 |
Why?
| Male | 92 | 2024 | 56103 | 0.760 |
Why?
| Female | 94 | 2024 | 60070 | 0.740 |
Why?
| Biosensing Techniques | 2 | 2020 | 102 | 0.730 |
Why?
| Uromodulin | 1 | 2019 | 21 | 0.670 |
Why?
| Glycopeptides | 1 | 2019 | 43 | 0.660 |
Why?
| Carotid Intima-Media Thickness | 3 | 2018 | 65 | 0.600 |
Why?
| Insulin Lispro | 4 | 2022 | 35 | 0.590 |
Why?
| Biomarkers | 10 | 2020 | 3474 | 0.580 |
Why?
| Ketones | 2 | 2016 | 44 | 0.570 |
Why?
| Child, Preschool | 19 | 2023 | 9164 | 0.560 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 373 | 0.550 |
Why?
| Autonomic Nervous System | 3 | 2013 | 70 | 0.520 |
Why?
| Adult | 53 | 2024 | 30814 | 0.520 |
Why?
| Cholesterol | 6 | 2020 | 368 | 0.510 |
Why?
| Diabetic Nephropathies | 5 | 2019 | 234 | 0.500 |
Why?
| Remote Consultation | 1 | 2015 | 42 | 0.490 |
Why?
| Patient Compliance | 2 | 2015 | 524 | 0.470 |
Why?
| Monitoring, Ambulatory | 4 | 2020 | 82 | 0.440 |
Why?
| Calcinosis | 4 | 2014 | 244 | 0.430 |
Why?
| Patient Education as Topic | 4 | 2019 | 685 | 0.430 |
Why?
| Cystatin C | 2 | 2015 | 61 | 0.420 |
Why?
| Diagnostic Techniques, Cardiovascular | 2 | 2014 | 11 | 0.420 |
Why?
| Case-Control Studies | 13 | 2020 | 3054 | 0.410 |
Why?
| Risk Factors | 27 | 2019 | 8715 | 0.410 |
Why?
| Glucagon | 3 | 2016 | 93 | 0.400 |
Why?
| Triglycerides | 9 | 2022 | 471 | 0.390 |
Why?
| Reproducibility of Results | 9 | 2024 | 2807 | 0.390 |
Why?
| Diabetic Ketoacidosis | 5 | 2022 | 159 | 0.380 |
Why?
| Algorithms | 11 | 2022 | 1494 | 0.380 |
Why?
| Arteries | 2 | 2010 | 250 | 0.380 |
Why?
| Insulin Aspart | 3 | 2022 | 26 | 0.380 |
Why?
| Self-Management | 2 | 2023 | 126 | 0.370 |
Why?
| Quality of Life | 5 | 2022 | 2390 | 0.370 |
Why?
| Graves Disease | 1 | 2010 | 32 | 0.360 |
Why?
| Adipose Tissue | 3 | 2022 | 553 | 0.350 |
Why?
| Friedreich Ataxia | 1 | 2010 | 64 | 0.330 |
Why?
| Middle Aged | 32 | 2023 | 27078 | 0.330 |
Why?
| Glomerular Filtration Rate | 4 | 2019 | 605 | 0.330 |
Why?
| Cholesterol, LDL | 4 | 2014 | 309 | 0.330 |
Why?
| Psychometrics | 3 | 2021 | 615 | 0.320 |
Why?
| Diabetes Complications | 2 | 2007 | 212 | 0.320 |
Why?
| Vascular Diseases | 2 | 2013 | 230 | 0.310 |
Why?
| Hyperlipidemias | 2 | 2007 | 123 | 0.300 |
Why?
| Skiing | 2 | 2019 | 40 | 0.300 |
Why?
| Pulse Wave Analysis | 10 | 2019 | 207 | 0.300 |
Why?
| Practice Guidelines as Topic | 1 | 2015 | 1405 | 0.300 |
Why?
| Insulin Resistance | 6 | 2019 | 1078 | 0.280 |
Why?
| Calibration | 4 | 2019 | 127 | 0.270 |
Why?
| Exercise | 5 | 2019 | 1611 | 0.260 |
Why?
| Coronary Artery Disease | 3 | 2007 | 613 | 0.260 |
Why?
| Receptors, Interleukin-2 | 1 | 2005 | 65 | 0.260 |
Why?
| Blood Pressure | 7 | 2014 | 1537 | 0.250 |
Why?
| Self Report | 2 | 2020 | 700 | 0.250 |
Why?
| Apolipoproteins B | 1 | 2014 | 41 | 0.250 |
Why?
| Heart Rate | 5 | 2019 | 700 | 0.240 |
Why?
| Body Mass Index | 10 | 2020 | 1974 | 0.230 |
Why?
| Infusion Pumps, Implantable | 2 | 2020 | 20 | 0.230 |
Why?
| Uric Acid | 2 | 2015 | 150 | 0.230 |
Why?
| Pilot Projects | 2 | 2020 | 1379 | 0.230 |
Why?
| Adiponectin | 4 | 2012 | 213 | 0.230 |
Why?
| Kidney | 3 | 2022 | 1210 | 0.220 |
Why?
| Diabetic Neuropathies | 3 | 2019 | 79 | 0.210 |
Why?
| Hypertension | 4 | 2019 | 1065 | 0.210 |
Why?
| Blood Vessels | 2 | 2018 | 181 | 0.210 |
Why?
| Lipids | 3 | 2014 | 589 | 0.210 |
Why?
| Cholesterol, HDL | 4 | 2014 | 185 | 0.210 |
Why?
| Insulin, Regular, Human | 4 | 2023 | 33 | 0.200 |
Why?
| Adiposity | 2 | 2018 | 468 | 0.200 |
Why?
| Age Factors | 9 | 2016 | 2911 | 0.200 |
Why?
| Computer Systems | 2 | 2018 | 46 | 0.190 |
Why?
| Technology | 1 | 2022 | 78 | 0.190 |
Why?
| Cohort Studies | 11 | 2017 | 4960 | 0.190 |
Why?
| Guideline Adherence | 2 | 2015 | 497 | 0.190 |
Why?
| Cross-Over Studies | 6 | 2019 | 437 | 0.190 |
Why?
| Glycosides | 1 | 2021 | 33 | 0.180 |
Why?
| Adolescent Behavior | 2 | 2017 | 480 | 0.180 |
Why?
| Microvessels | 2 | 2018 | 68 | 0.180 |
Why?
| Inpatients | 1 | 2024 | 380 | 0.180 |
Why?
| Prevalence | 6 | 2014 | 2270 | 0.170 |
Why?
| Sports | 2 | 2019 | 175 | 0.170 |
Why?
| Patient Dropouts | 1 | 2020 | 65 | 0.170 |
Why?
| Carotid Arteries | 2 | 2013 | 183 | 0.170 |
Why?
| Treatment Outcome | 11 | 2022 | 9163 | 0.170 |
Why?
| Coronary Vessels | 2 | 2014 | 230 | 0.170 |
Why?
| Brachial Artery | 3 | 2016 | 174 | 0.170 |
Why?
| Follow-Up Studies | 8 | 2019 | 4443 | 0.170 |
Why?
| Evidence-Based Medicine | 2 | 2014 | 685 | 0.170 |
Why?
| Administration, Intranasal | 2 | 2016 | 76 | 0.170 |
Why?
| Bacterial Vaccines | 1 | 1999 | 60 | 0.160 |
Why?
| Infant | 7 | 2019 | 7992 | 0.160 |
Why?
| Antihypertensive Agents | 3 | 2014 | 432 | 0.160 |
Why?
| Pneumococcal Infections | 1 | 1999 | 91 | 0.150 |
Why?
| Cardiotonic Agents | 1 | 2018 | 119 | 0.150 |
Why?
| Biomedical Technology | 1 | 2018 | 41 | 0.150 |
Why?
| Streptococcus pneumoniae | 1 | 1999 | 133 | 0.150 |
Why?
| Transplantation Conditioning | 1 | 2019 | 152 | 0.150 |
Why?
| Endocrinology | 1 | 2018 | 69 | 0.150 |
Why?
| Ohio | 5 | 2015 | 136 | 0.150 |
Why?
| Diabetic Cardiomyopathies | 2 | 2016 | 35 | 0.150 |
Why?
| Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 25 | 0.150 |
Why?
| Aged | 12 | 2023 | 19292 | 0.150 |
Why?
| Sex Factors | 5 | 2016 | 1741 | 0.140 |
Why?
| Risk Assessment | 4 | 2014 | 2992 | 0.140 |
Why?
| Cross-Sectional Studies | 7 | 2017 | 4447 | 0.140 |
Why?
| Regression Analysis | 4 | 2014 | 960 | 0.140 |
Why?
| Proprotein Convertase 9 | 1 | 2017 | 61 | 0.140 |
Why?
| Immunization | 1 | 1999 | 402 | 0.140 |
Why?
| Aorta | 1 | 2018 | 354 | 0.140 |
Why?
| Surveys and Questionnaires | 7 | 2021 | 4673 | 0.130 |
Why?
| Wyoming | 1 | 2015 | 18 | 0.130 |
Why?
| Inflammation | 2 | 2018 | 2502 | 0.130 |
Why?
| Colorado | 9 | 2017 | 4122 | 0.130 |
Why?
| Perception | 1 | 2018 | 316 | 0.130 |
Why?
| Coronary Disease | 3 | 2007 | 348 | 0.130 |
Why?
| Pediatric Obesity | 2 | 2019 | 492 | 0.130 |
Why?
| Periodontal Diseases | 1 | 2015 | 58 | 0.130 |
Why?
| Delivery of Health Care | 1 | 2022 | 847 | 0.130 |
Why?
| Metformin | 1 | 2018 | 278 | 0.130 |
Why?
| Lipoproteins | 2 | 2022 | 162 | 0.130 |
Why?
| Hormones | 1 | 2015 | 132 | 0.120 |
Why?
| Videoconferencing | 1 | 2015 | 57 | 0.120 |
Why?
| Consensus | 3 | 2023 | 531 | 0.120 |
Why?
| Hospitalization | 1 | 2024 | 1764 | 0.120 |
Why?
| Sleep | 2 | 2022 | 625 | 0.120 |
Why?
| Self Care | 2 | 2014 | 354 | 0.120 |
Why?
| Patient Satisfaction | 1 | 2018 | 585 | 0.120 |
Why?
| Atherosclerosis | 3 | 2015 | 341 | 0.120 |
Why?
| Vascular Calcification | 1 | 2016 | 108 | 0.120 |
Why?
| Circadian Rhythm | 2 | 2015 | 371 | 0.120 |
Why?
| Pandemics | 1 | 2022 | 1337 | 0.120 |
Why?
| Creatinine | 2 | 2015 | 431 | 0.120 |
Why?
| Ketosis | 1 | 2014 | 12 | 0.110 |
Why?
| Dietary Fiber | 1 | 2014 | 40 | 0.110 |
Why?
| Parents | 4 | 2022 | 1208 | 0.110 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 524 | 0.110 |
Why?
| Goals | 1 | 2015 | 159 | 0.110 |
Why?
| Pediatrics | 2 | 2018 | 985 | 0.110 |
Why?
| Monitoring, Physiologic | 1 | 2015 | 252 | 0.110 |
Why?
| Prognosis | 6 | 2020 | 3344 | 0.110 |
Why?
| Bionics | 2 | 2022 | 11 | 0.110 |
Why?
| Registries | 3 | 2020 | 1772 | 0.110 |
Why?
| Longitudinal Studies | 6 | 2016 | 2416 | 0.110 |
Why?
| Obesity | 3 | 2020 | 2523 | 0.110 |
Why?
| Acetaminophen | 1 | 2015 | 237 | 0.110 |
Why?
| Femoral Artery | 1 | 2013 | 168 | 0.100 |
Why?
| Vitamin D Deficiency | 1 | 2013 | 159 | 0.100 |
Why?
| Kidney Function Tests | 1 | 2011 | 141 | 0.090 |
Why?
| Precision Medicine | 1 | 2014 | 356 | 0.090 |
Why?
| Infant, Newborn | 4 | 2019 | 5084 | 0.090 |
Why?
| Thyroidectomy | 1 | 2010 | 52 | 0.090 |
Why?
| Vitamin D | 1 | 2013 | 341 | 0.090 |
Why?
| Injections, Subcutaneous | 2 | 2020 | 137 | 0.090 |
Why?
| United States | 8 | 2020 | 12319 | 0.090 |
Why?
| Hypolipidemic Agents | 2 | 2008 | 87 | 0.090 |
Why?
| Blood Flow Velocity | 2 | 2010 | 324 | 0.090 |
Why?
| Outpatients | 3 | 2021 | 330 | 0.090 |
Why?
| Glycosuria | 1 | 2009 | 8 | 0.090 |
Why?
| Diabetes Mellitus | 3 | 2018 | 905 | 0.080 |
Why?
| Double-Blind Method | 3 | 2021 | 1664 | 0.080 |
Why?
| Combined Modality Therapy | 3 | 2017 | 1127 | 0.080 |
Why?
| Mobile Applications | 2 | 2020 | 141 | 0.080 |
Why?
| Life Style | 2 | 2008 | 428 | 0.080 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.080 |
Why?
| Age Distribution | 2 | 2006 | 341 | 0.080 |
Why?
| Clinical Trials as Topic | 1 | 2012 | 944 | 0.070 |
Why?
| Cold Temperature | 2 | 2019 | 128 | 0.070 |
Why?
| Health Promotion | 1 | 2014 | 690 | 0.070 |
Why?
| Meals | 2 | 2019 | 101 | 0.070 |
Why?
| Disease Progression | 5 | 2018 | 2423 | 0.070 |
Why?
| Equipment Design | 2 | 2019 | 518 | 0.070 |
Why?
| Radionuclide Imaging | 1 | 2007 | 121 | 0.070 |
Why?
| Catheter Ablation | 1 | 2010 | 291 | 0.070 |
Why?
| Time Factors | 3 | 2014 | 6182 | 0.070 |
Why?
| Fetal Distress | 1 | 2006 | 12 | 0.070 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 72 | 0.070 |
Why?
| Smoking | 1 | 2014 | 1465 | 0.070 |
Why?
| Apolipoproteins A | 1 | 2006 | 18 | 0.070 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 180 | 0.070 |
Why?
| Polymorphism, Genetic | 2 | 2007 | 633 | 0.070 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1359 | 0.070 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2006 | 64 | 0.070 |
Why?
| Seasons | 2 | 2019 | 450 | 0.070 |
Why?
| Postprandial Period | 2 | 2018 | 88 | 0.070 |
Why?
| Hypertrophy | 2 | 2016 | 112 | 0.070 |
Why?
| Family Health | 1 | 2006 | 199 | 0.060 |
Why?
| Pregnancy in Diabetics | 1 | 2006 | 82 | 0.060 |
Why?
| Linear Models | 3 | 2014 | 777 | 0.060 |
Why?
| Infant, Newborn, Diseases | 1 | 2006 | 103 | 0.060 |
Why?
| Radiography | 1 | 2007 | 826 | 0.060 |
Why?
| Feasibility Studies | 2 | 2018 | 750 | 0.060 |
Why?
| Hair | 1 | 2004 | 66 | 0.060 |
Why?
| Prospective Studies | 3 | 2022 | 6276 | 0.060 |
Why?
| Sex Distribution | 1 | 2005 | 337 | 0.060 |
Why?
| Glucose Intolerance | 1 | 2005 | 137 | 0.060 |
Why?
| Cotinine | 1 | 2004 | 69 | 0.060 |
Why?
| Rats | 1 | 2012 | 5035 | 0.060 |
Why?
| Hemodynamics | 2 | 2022 | 969 | 0.060 |
Why?
| Stroke | 1 | 2012 | 1016 | 0.060 |
Why?
| Seizures | 1 | 2006 | 344 | 0.060 |
Why?
| Incidence | 3 | 2014 | 2336 | 0.060 |
Why?
| Inflammation Mediators | 1 | 2006 | 480 | 0.060 |
Why?
| Glucose | 2 | 2021 | 903 | 0.060 |
Why?
| Predictive Value of Tests | 3 | 2015 | 1813 | 0.050 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 351 | 0.050 |
Why?
| Chitinase-3-Like Protein 1 | 1 | 2022 | 17 | 0.050 |
Why?
| Societies, Medical | 2 | 2018 | 685 | 0.050 |
Why?
| Reference Values | 2 | 2018 | 745 | 0.050 |
Why?
| Tobacco Smoke Pollution | 1 | 2004 | 221 | 0.050 |
Why?
| Insulin-Secreting Cells | 1 | 2005 | 318 | 0.050 |
Why?
| Motor Activity | 2 | 2018 | 635 | 0.050 |
Why?
| Behavior Therapy | 1 | 2023 | 226 | 0.050 |
Why?
| Environmental Exposure | 1 | 2004 | 380 | 0.050 |
Why?
| Sitosterols | 1 | 2020 | 1 | 0.050 |
Why?
| Phytosterols | 1 | 2020 | 11 | 0.050 |
Why?
| Logistic Models | 1 | 2005 | 1863 | 0.050 |
Why?
| Intention to Treat Analysis | 1 | 2020 | 69 | 0.040 |
Why?
| Pancreas | 1 | 2022 | 280 | 0.040 |
Why?
| Social Conditions | 1 | 2019 | 12 | 0.040 |
Why?
| India | 1 | 2020 | 135 | 0.040 |
Why?
| Fear | 1 | 2022 | 296 | 0.040 |
Why?
| Autonomic Nervous System Diseases | 1 | 2019 | 27 | 0.040 |
Why?
| Retrospective Studies | 5 | 2014 | 12615 | 0.040 |
Why?
| Factor Analysis, Statistical | 1 | 2020 | 261 | 0.040 |
Why?
| Personal Satisfaction | 1 | 2021 | 185 | 0.040 |
Why?
| Vaccines, Conjugate | 1 | 1999 | 60 | 0.040 |
Why?
| Anthropometry | 1 | 2019 | 182 | 0.040 |
Why?
| Smartphone | 1 | 2019 | 68 | 0.040 |
Why?
| Waist Circumference | 1 | 2018 | 122 | 0.040 |
Why?
| Sex Characteristics | 2 | 2017 | 643 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2021 | 962 | 0.040 |
Why?
| International Cooperation | 1 | 2018 | 175 | 0.040 |
Why?
| Accelerometry | 1 | 2018 | 72 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 185 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2023 | 1217 | 0.040 |
Why?
| Virginia | 1 | 2017 | 53 | 0.040 |
Why?
| Ambulatory Care Facilities | 1 | 2019 | 211 | 0.040 |
Why?
| Age of Onset | 1 | 2018 | 455 | 0.040 |
Why?
| Magnetic Resonance Angiography | 1 | 2018 | 209 | 0.040 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.030 |
Why?
| Vascular Capacitance | 1 | 2016 | 3 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2019 | 643 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 3072 | 0.030 |
Why?
| Powders | 1 | 2016 | 38 | 0.030 |
Why?
| Food Preferences | 1 | 2017 | 108 | 0.030 |
Why?
| Family | 1 | 2020 | 597 | 0.030 |
Why?
| Equipment Failure | 1 | 2016 | 109 | 0.030 |
Why?
| Nausea | 1 | 2016 | 103 | 0.030 |
Why?
| Injections, Intramuscular | 1 | 2016 | 118 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2018 | 301 | 0.030 |
Why?
| Ankle Brachial Index | 1 | 2015 | 30 | 0.030 |
Why?
| Child Behavior | 1 | 2017 | 218 | 0.030 |
Why?
| Early Diagnosis | 1 | 2016 | 220 | 0.030 |
Why?
| International Agencies | 1 | 2014 | 29 | 0.030 |
Why?
| Apolipoproteins | 1 | 2014 | 36 | 0.030 |
Why?
| United States Food and Drug Administration | 1 | 2015 | 173 | 0.030 |
Why?
| Program Evaluation | 1 | 2019 | 841 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2015 | 515 | 0.030 |
Why?
| Patient Care Team | 1 | 2019 | 522 | 0.030 |
Why?
| Societies, Scientific | 1 | 2014 | 47 | 0.030 |
Why?
| Activities of Daily Living | 1 | 2017 | 352 | 0.030 |
Why?
| Adolescent Medicine | 1 | 2014 | 34 | 0.030 |
Why?
| China | 1 | 2014 | 165 | 0.030 |
Why?
| Pressure | 1 | 2014 | 219 | 0.030 |
Why?
| Nutrition Policy | 1 | 2014 | 54 | 0.030 |
Why?
| Primary Prevention | 1 | 2015 | 170 | 0.030 |
Why?
| Risk | 1 | 2016 | 829 | 0.030 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 242 | 0.030 |
Why?
| Fibrinogen | 1 | 2014 | 160 | 0.030 |
Why?
| Feeding Behavior | 1 | 2018 | 574 | 0.030 |
Why?
| Up-Regulation | 1 | 2015 | 824 | 0.030 |
Why?
| Diabetic Retinopathy | 1 | 2014 | 149 | 0.030 |
Why?
| American Heart Association | 1 | 2014 | 266 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 1871 | 0.020 |
Why?
| Genotype | 2 | 2007 | 1830 | 0.020 |
Why?
| Quality Improvement | 1 | 2019 | 958 | 0.020 |
Why?
| Animals | 1 | 2012 | 32158 | 0.020 |
Why?
| Practice Patterns, Physicians' | 1 | 2018 | 1182 | 0.020 |
Why?
| Pulsatile Flow | 1 | 2010 | 54 | 0.020 |
Why?
| Elasticity | 1 | 2010 | 194 | 0.020 |
Why?
| Arm | 1 | 2010 | 105 | 0.020 |
Why?
| South Carolina | 1 | 2008 | 40 | 0.020 |
Why?
| Lipoproteins, HDL | 1 | 2008 | 76 | 0.020 |
Why?
| Models, Biological | 1 | 2015 | 1647 | 0.020 |
Why?
| Nutrition Therapy | 1 | 2008 | 32 | 0.020 |
Why?
| Leg | 1 | 2010 | 227 | 0.020 |
Why?
| Lipoproteins, LDL | 1 | 2008 | 129 | 0.020 |
Why?
| Angiotensins | 1 | 2007 | 10 | 0.020 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 21 | 0.020 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2007 | 53 | 0.020 |
Why?
| Pancreatic Function Tests | 1 | 2005 | 3 | 0.020 |
Why?
| Amino Acid Substitution | 1 | 2006 | 267 | 0.020 |
Why?
| C-Peptide | 1 | 2005 | 137 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 2404 | 0.020 |
Why?
| Glucose Tolerance Test | 1 | 2005 | 344 | 0.010 |
Why?
| Population Surveillance | 1 | 2006 | 395 | 0.010 |
Why?
| Mother-Child Relations | 1 | 2004 | 109 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2008 | 845 | 0.010 |
Why?
| Oxidative Stress | 1 | 2006 | 1095 | 0.010 |
Why?
| DNA | 1 | 2006 | 1357 | 0.010 |
Why?
| Pregnancy | 1 | 2006 | 5555 | 0.010 |
Why?
|
|
Wadwa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|